{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:02:49Z","timestamp":1793865769803,"version":"4.6.1"},"reference-count":123,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>One-third of patients with acute severe ulcerative colitis (ASUC) are steroid-refractory. Cyclosporine and infliximab are currently the mainstays of salvage therapy. Janus kinase inhibitors (JAKi) could play a role in the treatment of ASUC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To review the evidence on JAKi in the management of ASUC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a bibliographic search to identify studies focusing on the treatment of ASUC with JAKi.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Potential advantages of JAKi for the management of ASUC include their oral administration, rapid onset of action, short half-life, lack of immunogenicity, and effectiveness in patients with prior biologic exposure. Thirty studies (including 373 patients) have evaluated the efficacy of tofacitinib in ASUC, with a response rate (avoidance of colectomy) ranging between 43% and 100%, with a weighted mean of 82%. Experience with upadacitinib is more limited (only 10 studies and 74 patients are available) but also encouraging: mean colectomy-free rate ranging between 67% and 100%, with a weighted mean of 79%. However, experience with filgotinib in ASUC is currently nonexistent. Regarding safety, the available data does not reveal any new safety concerns when JAKi are used in ASUC, although follow-up periods are still short.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>JAKi seems to be a promising treatment option for ASUC, with both tofacitinib and upadacitinib achieving colectomy-free rates of approximately 80%. Further studies are essential to define whether JAKi can replace cyclosporine\/infliximab as second-line therapy for the medical management of ASUC, or whether they can even be used as initial treatment in place of intravenous corticosteroids.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf021","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T12:26:31Z","timestamp":1738326391000},"source":"Crossref","is-referenced-by-count":24,"title":["Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3445","authenticated-orcid":false,"given":"Javier P","family":"Gisbert","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-4242","authenticated-orcid":false,"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"2025021309121172200_CIT0001","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bpg.2018.05.007","article-title":"Acute severe ulcerative colitis: state of the art treatment","volume":"32-33","author":"Gisbert","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol."},{"key":"2025021309121172200_CIT0002","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MOG.0000000000000637","article-title":"The management of the hospitalized ulcerative colitis patient: the medical-surgical conundrum","volume":"36","author":"Levy","year":"2020","journal-title":"Curr Opin Gastroenterol."},{"key":"2025021309121172200_CIT0003","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review","volume":"17","author":"Gisbert","year":"2023","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0004","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/gutjnl-2024-332489","article-title":"Acute severe ulcerative colitis trials: the past, the present and the future","volume":"73","author":"Honap","year":"2024","journal-title":"Gut."},{"key":"2025021309121172200_CIT0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2468-1253(23)00313-8","article-title":"Acute severe ulcerative colitis management: unanswered questions and latest insights","volume":"9","author":"Riviere","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ecco-jcc\/jjab177","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment","volume":"16","author":"Spinelli","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0007","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/apt.12473","article-title":"Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit","volume":"38","author":"Lynch","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"2025021309121172200_CIT0008","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3390\/jcm8122169","article-title":"Management of acute severe colitis in the era of biologicals and small molecules","volume":"8","author":"Verdon","year":"2019","journal-title":"J Clin Med."},{"key":"2025021309121172200_CIT0009","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.15592","article-title":"Systematic review with meta-analysis: mortality in acute severe ulcerative colitis","volume":"51","author":"Dong","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2025021309121172200_CIT0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jgh.14872","article-title":"The epidemiology of inflammatory bowel disease: East meets west","volume":"35","author":"Mak","year":"2020","journal-title":"J Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0011","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/CEG.S197719","article-title":"Optimal management of acute severe ulcerative colitis (ASUC): challenges and solutions","volume":"14","author":"Holvoet","year":"2021","journal-title":"Clin Exp Gastroenterol."},{"key":"2025021309121172200_CIT0012","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3390\/jpm14060580","article-title":"Current management of acute severe ulcerative colitis: new insights on the surgical approaches","volume":"14","author":"Lauricella","year":"2024","journal-title":"J Pers Med."},{"key":"2025021309121172200_CIT0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/bmb\/ldae006","article-title":"Management of acute severe ulcerative colitis-an update for generalist and specialist clinicians","volume":"151","author":"Kuriakose Kuzhiyanjal","year":"2024","journal-title":"Br Med Bull."},{"key":"2025021309121172200_CIT0014","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0015","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apt.13491","article-title":"Review article: the practical management of acute severe ulcerative colitis","volume":"43","author":"Seah","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"2025021309121172200_CIT0016","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MOG.0000000000000849","article-title":"Management of refractory inflammatory bowel disease","volume":"38","author":"Gergely","year":"2022","journal-title":"Curr Opin Gastroenterol."},{"key":"2025021309121172200_CIT0017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol."},{"key":"2025021309121172200_CIT0018","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.gastrohep.2019.03.002","article-title":"Efficacy of tofacitinib treatment in ulcerative colitis","volume":"42","author":"Panes","year":"2019","journal-title":"Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0019","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","article-title":"Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0020","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.dld.2021.04.018","article-title":"Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: a single-arm meta-analysis of observational studies","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig Liver Dis."},{"key":"2025021309121172200_CIT0021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12664-023-01507-9","article-title":"Tofacitinib use in ulcerative colitis: an expert consensus for day-to-day clinical practice","volume":"43","author":"Banerjee","year":"2024","journal-title":"Indian J Gastroenterol."},{"key":"2025021309121172200_CIT0022","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0023","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0024","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet."},{"key":"2025021309121172200_CIT0025","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"2025021309121172200_CIT0026","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0027","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0028","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cgh.2020.03.072","article-title":"Baseline clearance of infliximab is associated with requirement for colectomy in patients with acute severe ulcerative colitis","volume":"19","author":"Battat","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0029","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0030","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12664-024-01522-4","article-title":"Modern practical management of acute severe colitis","volume":"43","author":"AbdelMeguid","year":"2024","journal-title":"Indian J Gastroenterol."},{"key":"2025021309121172200_CIT0031","first-page":"2106","article-title":"Positioning tofacitinib in the treatment algorithm of moderate to severe ulcerative colitis","volume":"24","author":"Danese","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0032","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ecco-jcc\/jjad153","article-title":"Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis [ORCHID]: a prospective, open-label, randomized, pilot study","volume":"18","author":"Singh","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0033","author":"Berinstein"},{"key":"2025021309121172200_CIT0034","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.14309\/ajg.0000000000002145","article-title":"Real-world evidence of tofacinitib in ulcerative colitis: short-term and long-term effectiveness and safety","volume":"118","author":"Chaparro","year":"2023","journal-title":"Am J Gastroenterol."},{"key":"2025021309121172200_CIT0035","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"2025021309121172200_CIT0036","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5217\/ir.2024.00003","article-title":"What to do when traditional rescue therapies fail in acute severe ulcerative colitis","volume":"22","author":"Suen","year":"2024","journal-title":"Intest Res."},{"key":"2025021309121172200_CIT0037","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.14309\/ajg.0000000000002674","article-title":"Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multicenter experience","volume":"119","author":"Berinstein","year":"","journal-title":"Am J Gastroenterol."},{"key":"2025021309121172200_CIT0038","first-page":"97","article-title":"Successful initial tofacitinib treatment for acute severe ulcerative colitis with steroid resistance: a case series","volume":"36","author":"Komeda","year":"2023","journal-title":"Ann Gastroenterol."},{"key":"2025021309121172200_CIT0039","first-page":"e45416","article-title":"Tofacitinib in steroid-refractory acute severe ulcerative colitis: a retrospective analysis","volume":"15","author":"Malakar","year":"2023","journal-title":"Cureus."},{"key":"2025021309121172200_CIT0040","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/apt.16463","article-title":"Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: a GETAID cohort","volume":"54","author":"Uzzan","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"2025021309121172200_CIT0041","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1007\/s10620-022-07439-2","article-title":"Effectiveness of tofacitinib for hospitalized patients with acute severe ulcerative colitis: case series","volume":"67","author":"Xiao","year":"2022","journal-title":"Dig Dis Sci."},{"key":"2025021309121172200_CIT0042","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/ibd\/izaa157","article-title":"Tofacitinib in acute severe ulcerative colitis-a real-world tertiary center experience","volume":"26","author":"Honap","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0043","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/imj.16192","article-title":"Outcomes out to 12 months after sequential use of high-dose tofacitinib following infliximab in acute severe ulcerative colitis","volume":"53","author":"Eqbal","year":"2023","journal-title":"Intern Med J."},{"key":"2025021309121172200_CIT0044","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/jcm13030766","article-title":"Predictors of efficacy of janus kinase inhibitors in patients affected by ulcerative colitis","volume":"13","author":"Cuccia","year":"2024","journal-title":"J Clin Med."},{"key":"2025021309121172200_CIT0045","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/ibd\/izad183","article-title":"Factors associated with response to rescue therapy in acute severe ulcerative colitis","volume":"30","author":"Li Wai Suen","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0046","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European Evidence-based Consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0047","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/MEG.0000000000000187","article-title":"Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis","volume":"26","author":"Lowenberg","year":"2014","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0048","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0049","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel","year":"2011","journal-title":"Gastroenterology."},{"key":"2025021309121172200_CIT0050","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2010.12.028","article-title":"Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis","volume":"9","author":"Ardizzone","year":"2011","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0051","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.cgh.2020.08.001","article-title":"Evolution of endoscopic lesions in steroid-refractory acute severe ulcerative colitis responding to infliximab or cyclosporine","volume":"19","author":"Laharie","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0052","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik","year":"2021","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0053","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2468-1253(16)30016-4","article-title":"Infliximab or ciclosporin for acute severe ulcerative colitis","volume":"1","author":"Ananthakrishnan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0054","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.dld.2022.01.127","article-title":"Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig Liver Dis."},{"key":"2025021309121172200_CIT0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/00365521.2012.733954","article-title":"Cyclosporine in patients with severe steroid refractory ulcerative colitis in the era of infliximab. Review article","volume":"48","author":"Rolny","year":"2013","journal-title":"Scand J Gastroenterol."},{"key":"2025021309121172200_CIT0056","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2036.2005.02680.x","article-title":"Review article: how and when to use ciclosporin in ulcerative colitis","volume":"22","author":"Durai","year":"2005","journal-title":"Aliment Pharmacol Ther."},{"key":"2025021309121172200_CIT0057","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MCG.0000000000000779","article-title":"There is significant practice pattern variability in the management of the hospitalized ulcerative colitis patient at a tertiary care and IBD referral center","volume":"52","author":"Shah","year":"2018","journal-title":"J Clin Gastroenterol."},{"key":"2025021309121172200_CIT0058","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cgh.2008.08.029","article-title":"Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists","volume":"7","author":"Spiegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0059","first-page":"90","article-title":"Management of acute severe ulcerative colitis in Spain: a nationwide clinical practice survey","volume":"42","author":"Rodriguez-Lago","year":"2019","journal-title":"Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0060","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/2050640620977405","article-title":"Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: a multicentre cohort study","volume":"9","author":"Festa","year":"2021","journal-title":"United European Gastroenterol J."},{"key":"2025021309121172200_CIT0061","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12876-019-1085-y","article-title":"Patient views about the impact of ulcerative colitis and its management with drug treatment and surgery: a nested qualitative study within the CONSTRUCT trial","volume":"19","author":"Rapport","year":"2019","journal-title":"BMC Gastroenterol."},{"key":"2025021309121172200_CIT0062","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0063","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cgh.2020.07.046","article-title":"Tofacitinib is safe and effective when used in combination with infliximab for the management of refractory ulcerative colitis","volume":"19","author":"Gilmore","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0064","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1093\/ibd\/izab181","article-title":"Success of cyclosporin and tofacitinib combination therapy in a patient with severe steroid-refractory ulcerative colitis","volume":"27","author":"Yang","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0065","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/apt.17938","article-title":"Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)","volume":"59","author":"Garcia","year":"2024","journal-title":"Aliment Pharmacol Ther."},{"key":"2025021309121172200_CIT0066","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/ibd\/izab087","article-title":"Tofacitinib in acute severe ulcerative colitis: case series and a systematic review","volume":"27","author":"Jena","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0067","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.dld.2023.05.021","article-title":"The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: a systematic review","volume":"55","author":"Mpakogiannis","year":"2023","journal-title":"Dig Liver Dis."},{"key":"2025021309121172200_CIT0068","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for acute severe ulcerative colitis: a systematic review","volume":"17","author":"Steenholdt","year":"2023","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0069","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/ecco-jcc\/jjae111","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a systemic review and network meta-analysis","volume":"18","author":"Huang","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0070","doi-asserted-by":"publisher","first-page":"izae191","DOI":"10.1093\/ibd\/izae19","article-title":"Upadacitinib for acute severe ulcerative colitis: a systematic review","author":"Damianos","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0071","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cgh.2018.11.022","article-title":"Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis","volume":"17","author":"Berinstein","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0072","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/MPG.0000000000003616","article-title":"Tofacitinib salvage therapy for children hospitalized for corticosteroid- and biologic-refractory ulcerative colitis","volume":"75","author":"Constant","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2025021309121172200_CIT0073","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jcag\/gwad042","article-title":"The role of tofacitinib in the treatment of acute severe colitis in children","volume":"7","author":"Costaguta","year":"2024","journal-title":"J. Can. Assoc. Gastroenterol.."},{"key":"2025021309121172200_CIT0074","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/ibd\/izaa277","article-title":"Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease","volume":"27","author":"Dolinger","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0075","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.dld.2022.08.038","article-title":"Intentional treatment with tofacitinib in a patient with severe refractory ulcerative colitis and concomitant Sars-CoV-2 infection","volume":"54","author":"Festa","year":"2022","journal-title":"Dig Liver Dis."},{"key":"2025021309121172200_CIT0076","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gastrohep.2021.05.005","article-title":"Tofacitinib for the treatment of acute severe ulcerative colitis refractory to infliximab","volume":"45","author":"Fortuny","year":"2022","journal-title":"Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0077","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/ecco-jcc\/jjab109","article-title":"Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis","volume":"16","author":"Gilmore","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0078","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1097\/PG9.0000000000000241","article-title":"Tofacitinib to treat severe acute refractory colitis in a teenager: case report and review of the literature","volume":"3","author":"Girard","year":"2022","journal-title":"JPGN Rep."},{"key":"2025021309121172200_CIT0079","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.cgh.2018.11.038","article-title":"Rapid onset of tofacitinib induction therapy for the treatment of ulcerative colitis","volume":"17","author":"Griller","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0080","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.12998\/wjcc.v8.i24.6389","article-title":"Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report","volume":"8","author":"Komeda","year":"2020","journal-title":"World J Clin Cases."},{"key":"2025021309121172200_CIT0081","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/ecco-jcc\/jjaa018","article-title":"Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience","volume":"14","author":"Kotwani","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0082","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00535-023-02048-w","article-title":"Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis","volume":"58","author":"Naganuma","year":"2023","journal-title":"J Gastroenterol."},{"key":"2025021309121172200_CIT0083","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.gastrohep.2023.09.013","article-title":"Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience","volume":"47","author":"Parra-Izquierdo","year":"2024","journal-title":"Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0084","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.gastrohep.2023.10.003","article-title":"Colombian experience with the use of tofacitinib in severe acute ulcerative colitis: a case series study","volume":"47","author":"Parra-Izquierdo","year":"2024","journal-title":"Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0085","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/ibd\/izad135","article-title":"Real-life efficacy of tofacitinib in various situations in ulcerative colitis: a retrospective worldwide multicenter collaborative study","volume":"30","author":"Resal","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0086","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjaa198","article-title":"Tofacitinib therapy, the lender of last resort","volume":"15","author":"Rutka","year":"2021","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0087","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000514781","article-title":"An option for acute severe ulcerative colitis","volume":"29","author":"Santos","year":"2022","journal-title":"GE Port J Gastroenterol."},{"key":"2025021309121172200_CIT0088","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/ibd\/izaa357","article-title":"High-dose rescue tofacitinib prevented inpatient colectomy in acute severe ulcerative colitis refractory to anti-TNF","volume":"27","author":"Sedano","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0089","doi-asserted-by":"crossref","first-page":"e940966","DOI":"10.12659\/AJCR.940966","article-title":"Upadacitinib as a rescue therapy in acute severe ulcerative colitis: a case report and review of the literature","volume":"24","author":"Ali","year":"2023","journal-title":"Am J Case Rep."},{"key":"2025021309121172200_CIT0090","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s10620-024-08302-2","article-title":"Upadacitinib as rescue therapy for the treatment of acute severe colitis in an acute care setting","volume":"69","author":"Clinton","year":"2024","journal-title":"Dig Dis Sci."},{"key":"2025021309121172200_CIT0091","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ibd\/izae038","article-title":"Clinical outcomes at 8-16 weeks after upadacitinib initiation for acute severe ulcerative colitis: a case series in the United States","volume":"30","author":"Dalal","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0092","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/ecco-jcc\/jjad115","article-title":"Upadacitinib salvage therapy for infliximab-experienced patients with acute severe ulcerative colitis","volume":"17","author":"Gilmore","year":"2023","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0093","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jgh3.13015","article-title":"Upadacitinib in end stage renal disease: a case of acute severe ulcerative colitis","volume":"7","author":"Hilley","year":"2023","journal-title":"JGH Open."},{"key":"2025021309121172200_CIT0094","doi-asserted-by":"crossref","first-page":"446","DOI":"10.14740\/jocmr5005","article-title":"Upadacitinib plus intensive granulocyte and monocyte adsorptive apheresis for ulcerative colitis achieved ulcer healing for pyoderma gangrenosum","volume":"15","author":"Tanida","year":"2023","journal-title":"J Clin Med Res."},{"key":"2025021309121172200_CIT0095","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.12998\/wjcc.v12.i9.1685","article-title":"Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab: a case report","volume":"12","author":"Xu","year":"2024","journal-title":"World J Clin Cases."},{"key":"2025021309121172200_CIT0096","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10238-024-01468-z","article-title":"Effectiveness and safety of upadacitinib in acute severe ulcerative colitis patients from single Chinese IBD Center: a monocentric study","volume":"24","author":"Zhang","year":"2024","journal-title":"Clin Exp Med."},{"key":"2025021309121172200_CIT0097","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/ibd\/izad180","article-title":"Upadacitinib for acute severe ulcerative colitis","volume":"29","author":"Zinger","year":"2023","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0098","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet."},{"key":"2025021309121172200_CIT0099","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.cgh.2023.03.040","article-title":"Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real-world data","volume":"21","author":"Boneschansker","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0100","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/ibd\/izad279","article-title":"Use of upadacitinib in 16 tofacitinib-refractory ulcerative colitis patients: a single-center case 2Series","volume":"30","author":"Levine","year":"2023","journal-title":"Inflamm Bowel Dis."},{"key":"2025021309121172200_CIT0101","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1007\/s12325-024-02912-y","article-title":"Comparative efficacy and safety of upadacitinib vs. vedolizumab, ustekinumab, and tofacitinib after induction and maintenance for ulcerative colitis: three matching-adjusted indirect comparisons","volume":"41","author":"Reinisch","year":"2024","journal-title":"Adv Ther."},{"key":"2025021309121172200_CIT0102","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.14309\/ajg.0000000000002947","article-title":"Comparative effectiveness of upadacitinib and tofacitinib in ulcerative colitis: a us propensity-matched cohort study","volume":"119","author":"Kochhar","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"2025021309121172200_CIT0103","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.14309\/ajg.0000000000002746","article-title":"One-year comparative effectiveness of upadacitinib vs tofacitinib for ulcerative colitis: a multicenter cohort study","volume":"119","author":"Dalal","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"2025021309121172200_CIT0104","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1007\/s10620-024-08630-3","article-title":"Response to upadacitinib in patients with inflammatory bowel disease previously treated with tofacitinib","volume":"69","author":"Odah","year":"2024","journal-title":"Dig Dis Sci."},{"key":"2025021309121172200_CIT0105","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr","year":"2021","journal-title":"Gut."},{"key":"2025021309121172200_CIT0106","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0107","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/MEG.0000000000002751","article-title":"Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis","volume":"36","author":"Rokkas","year":"2024","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0108","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med."},{"key":"2025021309121172200_CIT0109","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.14309\/ajg.0000000000002598","article-title":"A Practical guide to the use of upadacitinib in ulcerative colitis and Crohn\u2019s disease","volume":"119","author":"Weiss","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"2025021309121172200_CIT0110","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med."},{"key":"2025021309121172200_CIT0111","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.dld.2024.03.010","article-title":"Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus","volume":"56","author":"Olivera","year":"2024","journal-title":"Dig Liver Dis."},{"key":"2025021309121172200_CIT0112","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/ueg2.12584","article-title":"Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure","volume":"12","author":"Panes","year":"2024","journal-title":"United European Gastroenterol J."},{"key":"2025021309121172200_CIT0113","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","article-title":"Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig Dis Sci."},{"key":"2025021309121172200_CIT0114","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/ueg2.12442","article-title":"Review article: updated management of acute severe ulcerative colitis: from steroids to novel medical strategies","volume":"11","author":"Calmejane","year":"2023","journal-title":"United European Gastroenterol J."},{"key":"2025021309121172200_CIT0115","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab Dispos."},{"key":"2025021309121172200_CIT0116","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/ecco-jcc\/jjaa028","article-title":"Tofacitinib for acute severe colitis: when the going gets tough, the tough get going","volume":"14","author":"D\u2019Amico","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2025021309121172200_CIT0117","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/codi.15702","article-title":"Perioperative safety of tofacitinib in surgical ulcerative colitis patients","volume":"23","author":"Lightner","year":"2021","journal-title":"Colorectal Dis."},{"key":"2025021309121172200_CIT0118","first-page":"693","article-title":"Tofacitinib is associated with increased risk of postoperative venous thromboembolism in patients with ulcerative colitis","volume":"67","author":"Russell","year":"2024","journal-title":"Dis Colon Rectum."},{"key":"2025021309121172200_CIT0119","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.cgh.2020.06.050","article-title":"Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis","volume":"19","author":"Deepak","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025021309121172200_CIT0120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2022.04.050","article-title":"PUCCINI: safety of anti-TNF in the perioperative setting","volume":"163","author":"Hyman","year":"2022","journal-title":"Gastroenterology."},{"key":"2025021309121172200_CIT0121","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/DCR.0000000000003440","article-title":"Tofacitinib exposure does not increase postoperative complications among patients with ulcerative colitis undergoing total colectomy: a retrospective case-control study","volume":"67","author":"Gomaa","year":"2024","journal-title":"Dis Colon Rectum."},{"key":"2025021309121172200_CIT0122","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.14309\/ajg.0000000000002676","article-title":"Rates of adverse events in patients with ulcerative colitis undergoing colectomy during treatment with tofacitinib vs biologics: a multicenter observational study","volume":"119","author":"Dragoni","year":"2024","journal-title":"Am J Gastroenterol."},{"key":"2025021309121172200_CIT0123","doi-asserted-by":"publisher","first-page":"S1542","DOI":"10.1016\/j.cgh.2024.06.050","article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","author":"Fudman","year":"2024","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf021\/61708794\/jjaf021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/2\/jjaf021\/61708794\/jjaf021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/2\/jjaf021\/61708794\/jjaf021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:14:09Z","timestamp":1739438049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf021\/7991529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf021","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,1,31]]},"article-number":"jjaf021"}}